Understanding Trade Margin Rationalisation in Medical Devices

Trade Margin Rationalisation (TMR) is a crucial topic in the healthcare sector, focusing on regulating trade margins for medical devices to alleviate patient costs. This article delves into the objectives of TMR, its historical context, and the potential benefits for patients. It also discusses the government's oversight on medical device pricing and the balance between profit margins and patient affordability. Understanding TMR's implications can provide insights into future healthcare policies and their impact on medical device pricing.

By Narendra Chaudhary Sep 26, 2026, 13:52 IST

Overview of Trade Margin Rationalisation (TMR)

The topic of Trade Margin Rationalisation (TMR) is gaining attention due to its implications on medical device pricing and treatment costs for patients. The primary goal of TMR is to rationalize the trade margins at various levels of the supply chain and to curb excessively high prices when necessary. The National Pharmaceutical Pricing Authority (NPPA) in India has previously implemented TMR on certain essential medical devices.

What is TMR?

Trade Margin Rationalisation (TMR) is a system designed to regulate or rationalize the trade margins applied from manufacturers to distributors and retailers. Its purpose is to ensure that patients do not have to pay exorbitant prices for medical devices due to excessive margins within the supply chain.

Previous Measures Before TMR

The government has historically employed various price control mechanisms for medical devices. For scheduled medical devices, the NPPA sets ceiling prices, while it also monitors prices for non-scheduled devices.

In March 2026, the government informed the Rajya Sabha that the Maximum Retail Price (MRP) for non-scheduled drugs and medical devices could not increase by more than 10% over the past year. The NPPA oversees pricing and can take action in cases of overcharging.

Medical Devices Previously Under TMR

In 2021, five key medical devices were included under the TMR system: pulse oximeters, blood pressure monitors, nebulizers, digital thermometers, and glucometers. The NPPA has documented notifications regarding TMR for these devices and subsequent extensions of its duration.

Additionally, a separate cap on trade margins was imposed for oxygen concentrators. According to government annual reports, this led to price reductions for 70 out of 252 products, with some retail prices dropping by as much as 54%.

Potential Relief for Patients

If a medical device's price includes excessive margins at various supply chain levels, limiting these trade margins could lead to lower final prices. This would directly impact the amount patients or customers have to pay.

However, the actual impact of any new TMR regulations will depend on which devices are included, the margin limits set, and how effectively the rules are enforced.

Government Oversight on Medical Device Pricing

In March 2026, the government stated that the NPPA monitors prices for both scheduled and non-scheduled medical devices. Complaints regarding pricing can be received through state drug controllers, Price Monitoring and Resource Units, market samples, and other grievance redressal mechanisms.

The government also clarified that there was no proposal under consideration for a nationwide uniform price cap for all essential medical devices under the 'One Nation, One Price' initiative.

Balancing Profit and Patient Costs

In the medical device industry, controlling prices must also consider the costs associated with research, production, importation, distribution, and technological development for companies. The government's policies on medical devices emphasize promoting domestic manufacturing and innovation. In 2026, the government provided support under plans to reduce reliance on imported medical devices.

Key Takeaways

TMR can be viewed as a regulatory tool aimed at rationalizing medical device prices. While government data indicates that previously implemented TMR has led to price reductions for some devices, the effects will not be uniform across all medical devices.

Therefore, if the scope of TMR is expanded in the future, the relief for patients will depend on which devices the government includes and the margin limits it establishes.